1. Home
  2. AIRE vs BLRX Comparison

AIRE vs BLRX Comparison

Compare AIRE & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo reAlpha Tech Corp.

AIRE

reAlpha Tech Corp.

HOLD

Current Price

$2.01

Market Cap

11.5M

Sector

N/A

ML Signal

HOLD

Logo BioLineRx Ltd.

BLRX

BioLineRx Ltd.

N/A

Current Price

$3.34

Market Cap

12.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
AIRE
BLRX
Founded
2021
2003
Country
United States
Israel
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
11.5M
12.6M
IPO Year
2023
2010

Fundamental Metrics

Financial Performance
Metric
AIRE
BLRX
Price
$2.01
$3.34
Analyst Decision
Buy
Strong Buy
Analyst Count
3
2
Target Price
$1.30
$19.00
AVG Volume (30 Days)
70.0K
29.1K
Earning Date
04-28-2026
05-26-2026
Dividend Yield
N/A
N/A
EPS Growth
60.34
N/A
EPS
N/A
N/A
Revenue
$4,518,498.00
N/A
Revenue This Year
$129.06
N/A
Revenue Next Year
$83.72
N/A
P/E Ratio
N/A
N/A
Revenue Growth
376.42
N/A
52 Week Low
$0.14
$2.15
52 Week High
$3.98
$5.05

Technical Indicators

Market Signals
Indicator
AIRE
BLRX
Relative Strength Index (RSI) 45.56 59.31
Support Level $1.89 $3.07
Resistance Level $2.77 $3.53
Average True Range (ATR) 0.19 0.24
MACD -0.05 -0.01
Stochastic Oscillator 12.30 81.15

Price Performance

Historical Comparison
AIRE
BLRX

About AIRE reAlpha Tech Corp.

ReAlpha Tech Corp is a real estate technology company. The group is engaged in an end-to-end commission-free homebuying platform. It develops and utilizes its artificial intelligence-focused technology stack to empower retail investor participation in short-term rental properties, which are real estate units listed for a rental term. It provides short-term rental investment opportunities to everyday investors. The company has developed technologies and tools that allow for the analysis of short-term rental properties using AI to provide insight into that property's potential profitability and ways to increase such profitability. The company's reportable segments are Homebuying Services and the Technology Services segment.

About BLRX BioLineRx Ltd.

BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.

Share on Social Networks: